@article{olivry_dunston_rivierre_jackson_murphy_peters_dean_2003, title={A randomized controlled trial of misoprostol monotherapy for canine atopic dermatitis: effects on dermal cellularity and cutaneous tumour necrosis factor-alpha}, volume={14}, ISSN={["0959-4493"]}, url={http://www.scopus.com/inward/record.url?eid=2-s2.0-0037310297&partnerID=MN8TOARS}, DOI={10.1046/j.1365-3164.2003.00323.x}, abstractNote={Abstract In this blinded randomized placebo‐controlled trial, 20 dogs with atopic dermatitis (AD) were given placebo (8 dogs) or misoprostol (12 dogs) at 5 µg kg−1, orally, three times daily for 3 weeks. Administration of the active drug, but not of placebo, led to a significant decrease in lesional and pruritus scores. The median reduction from baseline of both scores was ≈30%. Misoprostol therapy did not lead to decreases of dermal cell counts or skin tumour necrosis factor (TNF)α mRNA copy numbers that were significantly different from those of placebo. Skin TNFα protein production, assessed using indirect immunofluorescence, decreased or remained unchanged in dogs receiving misoprostol. In contrast, post treatment TNFα fluorescence scores were higher in all but two dogs given placebo. The changes from baseline of TNFα fluorescence scores did not correlate significantly with those of lesional or pruritus indices. These observations confirm the modest efficacy of misoprostol for treatment of canine AD and suggest that its mild anti‐allergic effects are not associated with either inhibition of inflammatory cell emigration or TNFα production.}, number={1}, journal={VETERINARY DERMATOLOGY}, author={Olivry, T and Dunston, SM and Rivierre, C and Jackson, HA and Murphy, KM and Peters, E and Dean, GA}, year={2003}, month={Feb}, pages={37–46} }
 @article{olivry_rivierre_murphy_2003, title={Efficacy of cyclosporine for treatment induction of canine pemphigus foliaceus}, volume={152}, ISSN={0042-4900 2042-7670}, url={http://dx.doi.org/10.1136/vr.152.2.53}, DOI={10.1136/vr.152.2.53}, abstractNote={NC 27606, USA CYCLOSPORINE (ciclosporine, cyclosporin A, CsA) is a cyclic oligopeptide which exhibits potent immunosuppressive properties by its ability to block the transcription of cytokine genes in activated T cells (Matsuda and Koyasu 2000). Because of its suppressive effect oiimnmuine cell activation, cyclosporine is being used with increasing frequency for the treatment of autoimmune and allergic skin diseases. Several case reports and small case studies have reported the benefit of cyclosporine for the treatmenit of human variants of pemphigus, an autoimmune disease directed against interkeratinocyte desmosomal adhesion molecules (Thivolet and others 1985, Balda and Rosenzweig 1986, Barthelemy and others 1988, Alijotas and others 1990, Bondesson and Hammar 1990, Campolmi and others 1991, Lapidoth and others 1994, Luisi and Stoukides 1994, Mobini and others 1997). In these studies, cyclosporine was effective either as a stand-alone treatment modality, or in combinaation with low immunosuppressive doses of oral glucocorticoids. Recently, a larger case study disputed the earlier findings of efficacy, as cyclosporine was found to offer Ino additional advantage over oral glucocorticoid monotherapy (loannides and others 2000). Thus, the issue ofwhether cyclosporine is of value in the treatment of human pemphigus variants remains uncertain. To date, the standard of care for treatment of canine pemphigus foliaceus (PF), the most common variant of pemphigus in animals, involves immuniosuppression with oral glucocorticoids used alone or in combination with cytotoxic drugs such as azathioprine (Olivry and Chan 2001). Unfortunately, the prolonged use of these medications is often followed by potentially life-threatening adverse drug effects. This short communication describes a pilot study to investigate whether cyclosporine monotherapy would be effective for the induction of treatment in dogs with PF. Five dogs diagnosed with n between June 2000 and February 2001 at the North Carolina State University Veterinary Teaching Hospital, USA, were selected for this clinical trial. In each case, the diagnosis of Pt was based on suggestive clinical signs, diagnostic histopathology, and the presence of skin-fixed and circulating anti-keratinocyte autoantibodies in direct and indirect immuniofluorescence assays, respectively (Olivry and Chan 2001). In addition, other pustular skin diseases, such as superficial pyoderma and pustular dermatophytosis, were ruled out using standard diagnostic and/or therapeutic methods. To document the severity of clinical signs of PF at each visit, a lesional score was designed and named the pemphigus foliaceus extent and severity index (I'EFESI). This scoring system consisted of the evaluation of the severity (0 none, 1 mild, 2 moderate and 3 severe) of the three cardinal lesions of PF (pustules, erosions and crusts) at 50 different areas covering the entire body surface. Even though the maximum PFETSI score theoretically achievable is 450 (3 x 3 x 50), the facialpedal predominant distribution of PF skin lesions usually results in a much lower score. Indeed, preliminary scoring of pretreatment skin lesions in 16 dogs with PF yielded PEFESI values ranging from 8 to 128 (mean 49, median 41) (T. Olivry, unpublished data). The primary outcome measure of this pilot trial was the reduction from the baseline of the PEFESI lesional score. 3}, number={2}, journal={Veterinary Record}, publisher={BMJ}, author={Olivry, T. and Rivierre, C. and Murphy, K. M.}, year={2003}, month={Jan}, pages={53–54} }
 @article{olivry_rivierre_jackson_murphy_davidson_sousa_2002, title={Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: a blinded randomized prednisolone-controlled trial}, volume={13}, ISSN={["0959-4493"]}, url={http://www.scopus.com/inward/record.url?eid=2-s2.0-0036546956&partnerID=MN8TOARS}, DOI={10.1046/j.1365-3164.2002.00283.x}, abstractNote={Abstract During the last decade, oral cyclosporin (CsA) has proven to be effective, in randomized controlled trials, for the treatment of atopic dermatitis (AD) in human patients. The purpose of this blinded randomized controlled trial was to test the hypothesis that CsA was successful in reducing the gravity of clinical signs of AD in dogs. Thirty dogs with nonseasonal AD were randomly allocated to receive an oral solution of either NEORAL CsA (5 mg kg−1) or prednisolone (0.5 mg kg−1) once daily for 6 weeks. Before, and 3 and 6 weeks after therapy, skin lesions were graded by clinicians using the Canine AD Extent and Severity Index (CADESI). Pruritus was assessed by the owners using a visual analog scale (PVAS). In both groups, CADESI and PVAS values were significantly lower at 6 weeks post treatment than before the initiation of therapy (Friedman test, P < 0.0004). The percentage reductions in CADESI and PVAS values from baseline were not statistically different between groups (Mann–Whitney test, P > 0.3). In this experiment, the tolerability and safety of oral CsA and prednisolone appeared similar. One‐fifth of dogs given oral CsA occasionally developed diarrhoea or soft stools. One dog that was given CsA developed a generalized papillomatous skin eruption during the second half of the trial. Our study provides randomized controlled trial evidence that CsA reduces the severity of clinical signs in dogs with nonseasonal AD. Moreover, the anti‐allergic efficacy of CsA appears comparable with that of prednisolone. We propose that oral CsA should be considered as a valuable alternative to glucocorticoid therapy in dogs with AD.}, number={2}, journal={VETERINARY DERMATOLOGY}, author={Olivry, T and Rivierre, C and Jackson, HA and Murphy, KM and Davidson, G and Sousa, CA}, year={2002}, month={Apr}, pages={77–87} }
 @article{rivierre_olivry_2001, title={New auto-immune diseases of dogs and cats, first part: diseases targeting hair follicle and basal keratinocytes}, volume={36}, number={6}, journal={Pratique Medicale et Chirurgicale de L'animal de Compagnie}, author={Rivierre, C. and Olivry, T.}, year={2001}, pages={635–644} }
 @article{rivierre_dunston_olivry_2000, title={Effects of a 1 percent hydrocortisone conditioner on the prevention of immediate and late-phase reactions in canine skin}, volume={147}, number={26}, journal={Veterinary Record}, author={Rivierre, C. and Dunston, S. M. and Olivry, T.}, year={2000}, pages={739–742} }
 @article{rivierre_olivry_1999, title={Paraneoplastic exfoliative dermatitis associated with thymomain cats. The resolution of symptoms after thymectomy}, volume={34}, number={4}, journal={Pratique Medicale et Chirurgicale de L'animal de Compagnie}, author={Rivierre, C. and Olivry, T.}, year={1999}, pages={531–537} }